WO2002002511A1 - Substituted benzamides for immune enhancement and for the treatment of cancer, infection and manic-depressive illness - Google Patents

Substituted benzamides for immune enhancement and for the treatment of cancer, infection and manic-depressive illness Download PDF

Info

Publication number
WO2002002511A1
WO2002002511A1 PCT/SE2001/001526 SE0101526W WO0202511A1 WO 2002002511 A1 WO2002002511 A1 WO 2002002511A1 SE 0101526 W SE0101526 W SE 0101526W WO 0202511 A1 WO0202511 A1 WO 0202511A1
Authority
WO
WIPO (PCT)
Prior art keywords
butyl
propyl
methyl
pentyl
iso
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/SE2001/001526
Other languages
English (en)
French (fr)
Inventor
Anders Björk
Gunnar Hedlund
Tomas Leanderson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Active Biotech AB
Original Assignee
Active Biotech AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech AB filed Critical Active Biotech AB
Priority to CA002414146A priority Critical patent/CA2414146C/en
Priority to AT01958717T priority patent/ATE277890T1/de
Priority to DK01958717T priority patent/DK1299350T3/da
Priority to JP2002507768A priority patent/JP4864273B2/ja
Priority to EP01958717A priority patent/EP1299350B1/en
Priority to DE60106036T priority patent/DE60106036T2/de
Priority to AU2001280338A priority patent/AU2001280338A1/en
Publication of WO2002002511A1 publication Critical patent/WO2002002511A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PCT/SE2001/001526 2000-07-05 2001-07-03 Substituted benzamides for immune enhancement and for the treatment of cancer, infection and manic-depressive illness Ceased WO2002002511A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002414146A CA2414146C (en) 2000-07-05 2001-07-03 Substituted benzamides for immune enhancement and for the treatment of cancer, infection and manic-depressive illness
AT01958717T ATE277890T1 (de) 2000-07-05 2001-07-03 Substituierte benzamide für die immunstärkung, die behandlung von krebs, infektionen und manisch-depressive erkrankungen
DK01958717T DK1299350T3 (da) 2001-07-03 2001-07-03 Substituerede benzamider til styrket immunforsvar og behandling af kræft, infektioner og manio-depressive sygdomme
JP2002507768A JP4864273B2 (ja) 2000-07-05 2001-07-03 免疫強化並びに癌、感染および躁鬱病の治療のための置換ベンズアミド
EP01958717A EP1299350B1 (en) 2000-07-05 2001-07-03 Substituted benzamides for immune enhancement and for the treatment of cancer, infection and manic-depressive illness
DE60106036T DE60106036T2 (de) 2000-07-05 2001-07-03 Substituierte Benzamide für die Immunstärkung, die Behandlung von Krebs, Infektionen und manisch-depressiven Erkrankungen
AU2001280338A AU2001280338A1 (en) 2000-07-05 2001-07-03 Substituted benzamides for immune enhancement and for the treatment of cancer, infection and manic-depressive illness

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0002531A SE0002531D0 (sv) 2000-07-05 2000-07-05 Immune Enhancement
SE0002531-2 2000-07-05

Publications (1)

Publication Number Publication Date
WO2002002511A1 true WO2002002511A1 (en) 2002-01-10

Family

ID=20280373

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2001/001526 Ceased WO2002002511A1 (en) 2000-07-05 2001-07-03 Substituted benzamides for immune enhancement and for the treatment of cancer, infection and manic-depressive illness

Country Status (10)

Country Link
EP (1) EP1299350B1 (https=)
JP (1) JP4864273B2 (https=)
AT (1) ATE277890T1 (https=)
AU (1) AU2001280338A1 (https=)
CA (1) CA2414146C (https=)
DE (1) DE60106036T2 (https=)
ES (1) ES2230350T3 (https=)
PT (1) PT1299350E (https=)
SE (1) SE0002531D0 (https=)
WO (1) WO2002002511A1 (https=)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE620543A (https=) *

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1525M (fr) * 1961-07-25 1962-11-16 Ile De France Médicaments antiémétiques nouveaux.
ES404497A1 (es) * 1972-06-20 1975-06-01 Miquel S A Lab Procedimiento para la obtencion de derivados de benzoileti-lendiaminas sustituidas.
EP0117462A3 (en) * 1983-02-28 1986-08-20 American Cyanamid Company N-(2-4-(1h-imidazol-1-yl)alkyl)arylamides
US4568685A (en) * 1984-02-29 1986-02-04 American Cyanamid Company N-[(1H-1,2,4-Triazol-1-yl)alkyl]-arylamides
US4820715A (en) * 1984-06-28 1989-04-11 Bristol-Myers Company Anti-emetic quinuclidinyl benzamides
CA2074061A1 (en) * 1991-08-26 1993-02-27 Ivo Monkovic Benzamide multidrug resistance reversing agents
WO1996040664A2 (en) * 1995-06-07 1996-12-19 Dade Chemistry Systems Inc. Preparation of immunogens and other conjugates of drugs
US6100299A (en) * 1996-03-08 2000-08-08 Oxigene, Inc. N-acetyl 3-chloroprocainamide, acid addition salts thereof, and methods of use
JP3933244B2 (ja) * 1997-04-04 2007-06-20 株式会社資生堂 アルキレンジアミン誘導体及び抗潰瘍剤、抗菌剤
JPH1180107A (ja) * 1997-09-01 1999-03-26 Japan Tobacco Inc 骨形成促進剤及びアミド化合物
JP2001151742A (ja) * 1999-11-26 2001-06-05 Mitsui Chemicals Inc アニリド誘導体及びそれを含有する抗不整脈剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE620543A (https=) *

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ERIC D. PESELOW ET AL.: "Clinical trials of benzamides in psychiatry", ADVANCED IN BIOCHEMICAL PSYCHOPHARMACOLOGY, vol. 35, 1982, pages 163 - 194, XP002948158 *
RONALD W. PERO ET AL.: "Newly discovered anti-inflammatory properties of the benzamides and nicotinamides", MOLECULAR AND CELLULAR BIOCHEMISTRY, vol. 193, 1999, pages 119 - 125, XP002948157 *

Also Published As

Publication number Publication date
DE60106036T2 (de) 2006-03-02
EP1299350A1 (en) 2003-04-09
JP4864273B2 (ja) 2012-02-01
ATE277890T1 (de) 2004-10-15
SE0002531D0 (sv) 2000-07-05
EP1299350B1 (en) 2004-09-29
PT1299350E (pt) 2005-01-31
DE60106036D1 (de) 2004-11-04
CA2414146C (en) 2008-11-25
CA2414146A1 (en) 2002-01-10
JP2004502668A (ja) 2004-01-29
AU2001280338A1 (en) 2002-01-14
ES2230350T3 (es) 2005-05-01

Similar Documents

Publication Publication Date Title
TWI332832B (en) Method for modulating calcium ion-release-activated calcium ion channels
US11339136B2 (en) Compounds and compositions for treating conditions associated with NLRP activity
EP0316594B1 (en) Aminomethyl oxooxazolidinyl ethenylbenzene derivatives useful as antibacterial agents
ES2401077T3 (es) Nuevos derivados 1,2-difenileteno para el tratamiento de enfermedades inmunológicas
JPH07503018A (ja) ピリジル置換イミダゾール
JP2024515062A (ja) 重水素化ｄｈｏｄｈ阻害剤
EA028077B1 (ru) N-(4-гидрокси-4-метилциклогексил)-4-фенилбензолсульфонамиды и n-(4-гидрокси-4-метилциклогексил)-4-(2-пиридил)бензолсульфонамиды и их терапевтическое применение
JPS61197554A (ja) 新規アニリド
WO1998022442A2 (en) Pharmaceutical compositions comprising diaryl-cyclomethylenpyrazole compounds and their use as cyclooxygenase i (cox 1) inhibitors
WO2000053172A1 (en) Ccr-3 receptor antagonists
US6518312B2 (en) Immune enhancement
CA1330446C (en) Phenolic thioalkylamides as inhibitors of 5-lipoxygenase
AU749643B2 (en) Method for treating protozoal infections
EP1299350B1 (en) Substituted benzamides for immune enhancement and for the treatment of cancer, infection and manic-depressive illness
KR20230143611A (ko) 바이사이클릭 고리를 포함하는 tyk2 억제제 화합물
AR022405A1 (es) Derivados de acido piroglutamico y compuestos relacionados que inhiben la adhesion de leucocitos intermediada por vla-4, composiciones farmaceuticas y eluso de los mismos para la manufactura de agentes y de medicamentos
WO2005084658A1 (en) Derivatives of actarit and their therapeutic use
US4024284A (en) Ethyl- and vinylbenzenes as anti-inflammatory agents
EP1083890A1 (en) N-acetyl 3-chloroprocainamide, acid addition salts thereof, and methods of use
US4567192A (en) Acylaminophenol derivatives
JPH0789920A (ja) 新規な化合物
US12528792B2 (en) Sulfonamide compounds and the use thereof in the treatment of cancer
SK282219B6 (sk) Farmaceutická zmes
CN114957148A (zh) 富马酸衍生物及其制备方法和医药用途
JP2007530594A (ja) 炎症及び免疫に関連する用途に用いられるアクリロニトリル誘導体

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001958717

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2414146

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2002 507768

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2001958717

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2001958717

Country of ref document: EP